Stockscreener 앱 받기
4.1057
1.10%
-0.0443
전일 마감가:
$4.15
열려 있는:
$4.13
하루 거래량:
1.70M
Relative Volume:
0.34
시가총액:
$1.32B
수익:
$360.78M
순이익/손실:
$-23.91M
주가수익비율:
-52.57
EPS:
-0.0781
순현금흐름:
$13.07M
1주 성능:
+5.24%
1개월 성능:
-0.62%
6개월 성능:
-25.91%
1년 성능:
-0.13%
1일 변동 폭
$4.06
$4.14
1주일 범위
$3.87
$4.40
52주 변동 폭
$2.23
$6.51
맨카인드 Stock (MNKD) Company Profile
명칭
Mannkind Corp
전화
818-661-5000
주소
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.105 | 1.37B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
550.42 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
829.89 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,014.42 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.21 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.13 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
맨카인드 Stock (MNKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-10-10 | 개시 | Leerink Partners | Outperform |
| 2025-07-16 | 재개 | H.C. Wainwright | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-10 | 개시 | Wedbush | Outperform |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-12-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-10 | 개시 | Wedbush | Outperform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 개시 | Oppenheimer | Outperform |
| 2019-10-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2018-02-28 | 다운그레이드 | Maxim Group | Hold → Sell |
| 2017-11-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-10 | 개시 | H.C. Wainwright | Buy |
| 2017-10-06 | 재확인 | Maxim Group | Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-05-10 | 재확인 | Piper Jaffray | Underweight |
| 2016-05-10 | 재확인 | RBC Capital Mkts | Underperform |
| 2016-01-06 | 재확인 | Piper Jaffray | Underweight |
| 2016-01-06 | 재확인 | RBC Capital Mkts | Underperform |
| 2015-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | 다운그레이드 | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-05-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 재확인 | MLV & Co | Hold |
| 2015-04-16 | 재확인 | RBC Capital Mkts | Outperform |
모두보기
맨카인드 주식(MNKD)의 최신 뉴스
MannKind Corporation Submits Prospectus Supplement with Legal Opinion on Common Stock Offering - Kalkine Media
MannKind (NASDAQ: MNKD) resale taps $0.01 warrant shares - Stock Titan
MannKind files legal opinion for common stock offering under shelf registration - TradingView
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story - simplywall.st
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake - Stock Titan
Research Analysts Set Expectations for MannKind Q3 Earnings - MarketBeat
MNKD Stock Price, Quote & Chart - ChartMill
MannKind FY2029 EPS Estimate Decreased by HC Wainwright - MarketBeat
MannKind gains FDA approvals, boosting growth p... - Pluang
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - Taiwan News
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com - Investing.com UK
MannKind Corp (MNKD) Director Steven Binder Sells 39,051 Shares - GuruFocus
Mannkind director Steven Binder sells $158,547 in common stock - Investing.com India
Steven Binder Sells 39,051 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Sei Investments Co. Buys 253,537 Shares of MannKind Corporation $MNKD - MarketBeat
First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD - MarketBeat
Dimensional Fund Advisors LP Acquires 509,692 Shares of MannKind Corporation $MNKD - marketbeat.com
MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen - MarketBeat
MannKind (MNKD) insider Steven Binder plans 39,051-share Rule 144 stock sale - Stock Titan
Danbury biopharma company expands workforce, manufacturing amid new product launches - Hartford Business Journal
MannKind (NASDAQ:MNKD) Upgraded by Zacks Research to Hold Rating - MarketBeat
Empowered Funds LLC Invests $1.88 Million in MannKind Corporation $MNKD - MarketBeat
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 By Investing.com - Investing.com South Africa
MNKD Maintained by Wells Fargo -- Price Target Lowered to $13.00 - GuruFocus
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says - Yahoo Finance
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 - Investing.com
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts Drive Growth - GuruFocus
MannKind Q2 Earnings Call Highlights - marketbeat.com
MNKD SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MannKind (NASDAQ:MNKD) Announces Quarterly Earnings Results - MarketBeat
Earnings call transcript: MannKind tops revenue forecast in Q2 2026 By Investing.com - Investing.com Nigeria
Earnings call transcript: MannKind tops revenue forecast in Q2 2026 - Investing.com
Is MannKind Corp (MNKD) Positioned for Growth After Q2 Earnings? - GuruFocus
MannKind Q2 2026 slides: revenue surges 43%, marketed products lead - Investing.com
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
MannKind: Q2 Earnings Snapshot - Barchart.com
MannKind Corp Q2 2026: Revenue $109.4M, EPS $(0.06) — 10-Q Summary - TradingView
MannKind (NASDAQ: MNKD) posts $199M H1 2026 revenue after scPharma deal - Stock Titan
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
MannKind earnings in focus after FUROSCIX ReadyFlow approval By Investing.com - Investing.com Nigeria
MannKind Corp expected to post breakeven results a shareEarnings Preview - TradingView
MannKind Corp (MNKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
MannKind Reports Positive Topline Results from Phase 1b INFLO-1 Study of Nintedanib Dry Powder Inhalation in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF - GlobeNewswire
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway - Yahoo Finance
MannKind will review second-quarter results in Aug. 5 webcast - Stock Titan
맨카인드 (MNKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.14%
0.28%
자본화:
|
볼륨(24시간):